Pirepemat
Pirepemat (IRL752) is a corticalpreferring catecholamine- and cognition-promoting agent. Pirepemat (IRL752) is used for the study of Parkinson's disease. IRL752 is a selective enhancer of cortical dopamine, acetylcholine and norepinephrine.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 1227638-29-0
- Fòrmula: C11H13F2NO
- Peso molecular:213.22
-
Almacenamiento:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Ver todos los productos específicos de isoformas Dopamine Receptor
MoreVer todos los productos específicos de isoformas Adrenergic Receptor
More
Actividad biológica
Descripciòn
In Vitro
IRL752 displayed its highest in vitro affinities for 5-HT and NA-related targets[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Normal rats[2].
-
Dosage:3.7-100 µmol/kg.
-
Administration:s.c., 30 min prior to testing.
-
Result:Induced dose-dependent and regio-selective alterations in brain monoamine transmission indices and gene expression.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 1227638-29-0
-
Appearance Oil
-
Peso molecular 213.22
-
Fòrmula C11H13F2NO
-
Color Off-white to brown
-
SMILES
CO[C@]1(C(C=CC=C2F)=C2F)CCNC1
-
Synonyms
IRL752
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Protocolo
-
Human pluripotent stem cell midbrain dopaminergic neuron differentiation
Human pluripotent stem cells are directed toward midbrain dopaminergic neurons by first inducing a neural floor-plate-like progenitor state, then patterning cells with ventralizing SHH signaling and midbrain/WNT-FGF cues, and finally maturing progenitors into neurons expressing dopaminergic markers such as TH, NURR1/NR4A2, PITX3, DAT/SLC6A3, VMAT2/SLC18A2, GIRK2/KCNJ6, FOXA2, LMX1A, and EN1. The main readouts are loss of pluripotency, acquisition of FOXA2+/LMX1A+ midbrain floor-plate progenitors, emergence of βIII-tubulin+/MAP2+ neurons, and production of TH+ dopaminergic neurons with molecular, dopamine-release, and electrophysiological features of midbrain dopaminergic identity.
Pureza y Documentación
-
Ficha de datos (275 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Systematic review of pharmacological interventions for people with Lewy body dementia
[3]. S Hjorth, et al. (3 S)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine (IRL752) -a Novel Cortical-Preferring Catecholamine Transmission- and Cognition-Promoting Agent. J Pharmacol Exp Ther. 2020 Sep;374(3):404-419. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)